What is Angiocrine Bioscience?
Angiocrine Bioscience operates at the intersection of biotechnology and advanced clinical care, specializing in the development of E-CEL Therapies. These innovative cellular platforms are engineered to facilitate the restoration, regeneration, and repair of damaged tissues and organs. By focusing on the fundamental mechanisms of cellular interaction, the company aims to address critical unmet needs in patient care, moving beyond symptomatic treatment toward curative, regenerative outcomes. Their market position is defined by a commitment to high-impact therapeutic solutions that leverage the body's innate capacity for healing, positioning them as a key player in the evolving landscape of regenerative medicine.
How much funding has Angiocrine Bioscience raised?
Angiocrine Bioscience has raised a total of $2.3M across 2 funding rounds:
Debt
$150K
Private Equity
$2.1M
Debt (2020): $150K with participation from PPP
Private Equity (2025): $2.1M, investors not publicly disclosed
Key Investors in Angiocrine Bioscience
Undisclosed Investor
A private equity firm focused on long-term capital appreciation within the high-growth biotechnology and life sciences sectors.
PPP
Public-Private Partnership
Undisclosed Investor
An institutional investor specializing in early-to-mid stage regenerative medicine and cellular therapy research.
What's next for Angiocrine Bioscience?
With the recent influx of capital, Angiocrine Bioscience is well-positioned to accelerate its clinical development pipeline and scale its manufacturing capabilities for E-CEL Therapies. The strategic focus will likely shift toward expanding human clinical trials and refining the delivery mechanisms for their regenerative assets. As the company transitions into this next phase of growth, the emphasis will remain on validating the efficacy of their cellular therapies in complex organ repair scenarios, ultimately aiming to secure regulatory milestones that will facilitate broader commercial adoption and long-term therapeutic impact in the global healthcare market.
See full Angiocrine Bioscience company page
